Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia…

(MENAFN - GetNews) Hemophilia Treatment Global Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User Global Forecast Till 2023

Hemophilia Treatment Market Overview

The global hemophilia market is forecasted to witness a steady growth of 6.10% during the forecast period between 2018 to 2023. The market valuation is slated to jump from USD 11,257.21 in 2017 to USD 16,059.17 by the end of the forecast period.

Request Free Sample Copy Available @ https://www.marketresearchfuture.com/sample_request/5688

The report published by Market Research Future (MRFR) identifies that the prevalence of hemophilia will spring up the demand for hemophilia treatment globally. The emergence of recombinant products for the treatment of hemophilia has blossomed the interest and demand for the market. The absence of a precise cure and the growing setbacks with the treatment of hemophilia has increased the need for discovering and coming up with new and effective solutions. Gene therapy is increasingly being explored and considered as a permanent solution for hemophilia and offers vast opportunities for the growth of the market.

However, the high cost associated with the treatment and the level of expenses required for consistent lab testing and imaging tests can go on to hamper the market growth of hemophilia treatment.

Hemophilia Treatment Market Segmentation

The global hemophilia treatment market segmentation is based in terms of type, end-user, and treatment.

By type, the market is categorized into hemophilia A, hemophilia B, and hemophilia C. The hemophilia A segment holds the largest share of the global market. The valuation of the segment is expected to reach USD 12.697.99 by the end of the forecast period, 2023. The calculated growth rate of the market annually has been projected to be 6.23% during the forecast period.

By treatment, the market comprises of recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, desmopressin, gene therapy, and antifibrinolytic agents. The recombinant coagulation factor concentrates is the largest market share holder with an expected CAGR of 7.01% during the review period.

By end-users, the market includes hospitals & clinics, research organization, and others. Hospitals & clinics lead this segmentation of the market and is valued at USD 7594.66 in 2017 and is expected to grow the fastest over the forthcoming years.

Hemophilia Treatment Market Regional Analysis

The regional segmentation of the hemophilia treatment market covers the following regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The Americas stand tall as the largest market share holder in the global geographical segmentation. This is due to the prevalence of the hemophilia disorder and the presence of a well-established healthcare sector. Growing expenditure in healthcare and increasing support for research and development activities are expected to aid the Americas region to maintain its leadership position. The North American market contributes more to the region than its southern counterpart.

Europe holds the second biggest market share due to a parallel growth pattern like the Americas. Moreover, government support for R & D activities for advanced medical therapies for hemophilia is another important driver to the market growth in this region.

Asia Pacific is expected to grow with the highest CAGR of 8.38% during the review period. The healthcare sector in this region is advancing at a rapid pace owing to the high disposable income in the region and expanding advanced medical facilities. The presence of a vast patient population base and a high healthcare expenditure is expected to positively impact the Asia Pacific market growth.

Hemophilia Treatment Market Competitive Landscape

The global hemophilia treatment market includes various noteworthy players like Baxter, F.Hoffmann-La Roche Ltd, Octapharma, Swedish Orphan Biovitrum AB, Pfizer Inc, CSL Behring, Sanofi, Kedrion, Novo Nordisk A/S, Bayer AG, Grifols International S.A, and Shire.

Feb 19th, 2019, Novo Nordisk announced in a press release about the US FDA approval of N8-GP, turoctocog alfa pegol, to help treat children and adults with hemophilia A in the United States. The therapy will be under the brand name of Esperoct

Feb 7th, 2019, Roche announced its joining with the World Federation of Hemophilia (WFH) Humanitarian Aid Program. The program will see the company treating more than 1,500 people with Hemophilia A across various developing countries.

Read Complete Report @ https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688

MENAFN1811201900703268ID1099290278

Read this article:
Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia...

Global Regenerative Therapies for Osteoarthritis Market Insights 2019 : Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma – Breakaway Trends

The global "Regenerative Therapies for Osteoarthritis Market" report offers the analyzed data of the Regenerative Therapies for Osteoarthritis market in categorized view. The Regenerative Therapies for Osteoarthritis market offers a common platform with multiple opportunities to many firms, associations, industries, and other products and services providers Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma, Organovo, Orgenesis, Sanofi, Athersys, Shire, Cytori Therapeutics to compete among themselves by offering better products and acceptable services to the clients and expand significantly at the global level. The global Regenerative Therapies for Osteoarthritis market report offers summarized detail about the major market holding key contenders alongside the recent developing industries in the market relating to the revenue, demands, sales, and product quality.

Apply here for the sample copy of the report @: https://www.reportsbuzz.com/request-for-sample.html?repid=78717

Furthermore, The report presents a detailed segmentation Cell Therapy, Tissue Engineering, Gene Therapy, Market Trend by Application Hospitals, Ambulatory Surgical Centers, Orthopaedic Clinics, Research Institutes of the global market based on technology, product type, application, and various processes and systems. The report contains information on a large number of highly reputed organizations, vendors, and manufacturers in the global Regenerative Therapies for Osteoarthritis market.

The current status and future outlook of the market growth is also included in the Regenerative Therapies for Osteoarthritis market report. The report is created after deep research and thorough investigation of the gathered data in different divisions of the market that needs technological ideas, theoretical analysis, and its relevancy. The report includes the various key factors that can considerably accelerate and slow down the growth rate of the market. The report provides information about the future development of the industry, based on its past data along with the current evaluated data about the Regenerative Therapies for Osteoarthritis market region-wise.

Read Detailed Index of full Research Study at:: https://www.reportsbuzz.com/78717/global-regenerative-therapies-for-osteoarthritis-market-outlook-2018/

To provide the clarified representation of the current and upcoming growth trends of the market, the report provides the execution and attributes of the Regenerative Therapies for Osteoarthritis market that are analyzed on the basis of the qualitative and quantitative process. Through the report, one can be able to take quick and precise business decisions by getting familiar with every aspect of the market. The Regenerative Therapies for Osteoarthritis market report represents the analyzed data through graphs, charts, and figures for less complexity and better understandability about the Regenerative Therapies for Osteoarthritis market.

There are 15 Chapters to display the Global Regenerative Therapies for Osteoarthritis market

Chapter 1, Definition, Specifications and Classification of Regenerative Therapies for Osteoarthritis, Applications of Regenerative Therapies for Osteoarthritis, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Regenerative Therapies for Osteoarthritis, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Regenerative Therapies for Osteoarthritis Segment Market Analysis (by Type);Chapter 7 and 8, The Regenerative Therapies for Osteoarthritis Segment Market Analysis (by Application) Major Manufacturers Analysis of Regenerative Therapies for Osteoarthritis ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Cell Therapy, Tissue Engineering, Gene Therapy, Market Trend by Application Hospitals, Ambulatory Surgical Centers, Orthopaedic Clinics, Research Institutes;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Regenerative Therapies for Osteoarthritis ;Chapter 12, Regenerative Therapies for Osteoarthritis Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Regenerative Therapies for Osteoarthritis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: https://www.reportsbuzz.com/inquiry-for-buying.html?repid=78717

Reasons for Buying Regenerative Therapies for Osteoarthritis market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

Read the original:
Global Regenerative Therapies for Osteoarthritis Market Insights 2019 : Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma - Breakaway Trends

WCM-Q explores law and ethics of stem cells and AI in medicine – The Peninsula Qatar

18 Nov 2019 - 8:02

Speakers at WCM-Qs Law and Medicine event taking part in a panel discussion on the law and ethics of stem cell science.

The legal and ethical implications of using stem cells and artificial intelligence (AI) in medicine were discussed at the latest instalment of Weill Cornell Medicine-Qatars (WCM-Q) Intersection of Law & Medicine series.Expert speakers at the event discussed the impact of recent advances in stem cell science and AI on the practice of medicine in Qatar and explored how new legal frameworks could be developed to protect the rights and safety of patients in the MENA region. The day-long event was organized by WCM-Q in collaboration with Hamad Bin Khalifa University and the University of Malaya of Kuala Lumpur, Malaysia.Stem cells are an exciting area for medical researchers because they have the potential to repair damaged or diseased tissues in people with conditions such as Parkinsons disease, type 1 diabetes, stroke, cancer, and Alzheimers disease, among many others. Stem cells can also be used by researchers to test new drugs for safety and effectiveness.WCM-Qs Dr. Amal Robay, WCM-Q assistant professor in genetic medicine and director of research compliance, said: Stem cells have the capacity for unlimited or prolonged self-renewal, and they can differentiate themselves into many different cell types to become tissue- or organ-specific cells with special functions. The central ethical dilemma of stem cell science arises from the fact that embryonic stem cells are derived from human embryos or by cloning, she explained.Visiting bioethics expert Dr. Jeremy Sugarman of Johns Hopkins University in Baltimore, US said that the public image of stem cell research had been damaged by a small number of high-profile cases in which scientists had behaved unethically. The field had also been hampered by different countries applying different laws to stem cell research, making international collaboration problematic, he said.Meanwhile, the use of AI in healthcare has the potential to leverage analysis of large amounts of data to improve patient outcomes, but poses ethical concerns regarding privacy, the diversity of data sources, biases and relying on non-human entities for potentially life-changing decisions.Dr. Barry Solaiman, assistant professor of law in the College of Law and Public Policy at HBKU said: Its very important that we bridge that gap between the professions of law and medicine, and that we understand the fundamental importance of ethicists to the advance of science. We need to consider how lawyers can help to develop laws to ensure that science advances and that it does so in ways that protect everyone involved.The event, which was co-directed by Dr. Solaiman and Dr. Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q, also featured other expert speakers.The event was accredited locally by the Qatar Council for Healthcare Practitioners-Accreditation Department (QCHP-AD) and internationally by the Accreditation Council for Continuing Medical Education (ACCME).

Follow this link:
WCM-Q explores law and ethics of stem cells and AI in medicine - The Peninsula Qatar

Qatar- WCM-Q explores law and ethics of stem cells and AI in medicine – MENAFN.COM

(MENAFN - The Peninsula) The legal and ethical implications of using stem cells and artificial intelligence (AI) in medicine were discussed at the latest instalment of Weill Cornell Medicine-Qatar's (WCM-Q) Intersection of Law & Medicine series.Expert speakers at the event discussed the impact of recent advances in stem cell science and AI on the practice of medicine in Qatar and explored how new legal frameworks could be developed to protect the rights and safety of patients in the MENA region. The day-long event was organized by WCM-Q in collaboration with Hamad Bin Khalifa University and the University of Malaya of Kuala Lumpur, Malaysia.Stem cells are an exciting area for medical researchers because they have the potential to repair damaged or diseased tissues in people with conditions such as Parkinson's disease, type 1 diabetes, stroke, cancer, and Alzheimer's disease, among many others. Stem cells can also be used by researchers to test new drugs for safety and effectiveness.WCM-Q's Dr. Amal Robay, WCM-Q assistant professor in genetic medicine and director of research compliance, said: 'Stem cells have the capacity for unlimited or prolonged self-renewal, and they can differentiate themselves into many different cell types to become tissue- or organ-specific cells with special functions. The central ethical dilemma of stem cell science arises from the fact that embryonic stem cells are derived from human embryos or by cloning, she explained.Visiting bioethics expert Dr. Jeremy Sugarman of Johns Hopkins University in Baltimore, US said that the public image of stem cell research had been damaged by a small number of high-profile cases in which scientists had behaved unethically. The field had also been hampered by different countries applying different laws to stem cell research, making international collaboration problematic, he said.Meanwhile, the use of AI in healthcare has the potential to leverage analysis of large amounts of data to improve patient outcomes, but poses ethical concerns regarding privacy, the diversity of data sources, biases and relying on non-human entities for potentially life-changing decisions.Dr. Barry Solaiman, assistant professor of law in the College of Law and Public Policy at HBKU said: 'It's very important that we bridge that gap between the professions of law and medicine, and that we understand the fundamental importance of ethicists to the advance of science. We need to consider how lawyers can help to develop laws to ensure that science advances and that it does so in ways that protect everyone involved.The event, which was co-directed by Dr. Solaiman and Dr. Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q, also featured other expert speakers.The event was accredited locally by the Qatar Council for Healthcare Practitioners-Accreditation Department (QCHP-AD) and internationally by the Accreditation Council for Continuing Medical Education (ACCME).

MENAFN1811201900630000ID1099287087

View original post here:
Qatar- WCM-Q explores law and ethics of stem cells and AI in medicine - MENAFN.COM

New cell therapy improves memory and stops seizures after brain injury – Drug Target Review

A recent study has shown that transplanting new inhibitory neurons may repair damaged brain circuits.

A breakthrough cell therapy to improve memory and prevent seizures in mice following traumatic brain injury (TBI) has been developed by researchers.

In the study, the research team from the University of California, US transplanted embryonic progenitor cells capable of generating inhibitory interneurons (a specific type of nerve cell that controls the activity of brain circuits) into the brains of mice with traumatic brain injury, targeting the hippocampus.

These are transplanted inhibitory neurons (green) successfully incorporated into the hippocampus of a mouse with traumatic brain injury (credit: UCI School of Medicine).

The researchers discovered that the transplanted neurons migrated into the injury where they formed new connections with the injured brain cells and thrived long term. Within a month after the treatment, the mice models showed signs of memory improvement.

The cell transplants also prevented the mice from developing epilepsy, which affected more than half of the mice who were not treated with new interneurons.

Inhibitory neurons are critically involved in many aspects of memory, and they are extremely vulnerable to dying after a brain injury, said Robert Hunt, PhD, assistant professor of anatomy and neurobiology at UCI School of Medicine who led the study. While we cannot stop interneurons from dying, it was exciting to find that we can replace them and rebuild their circuits.

To further test their observations, the team silenced the transplanted neurons with a drug, which caused the memory problems to return.

It was exciting to see the animals memory problems come back after we silenced the transplanted cells, because it showed that the new neurons really were the reason for the memory improvement, added Bingyao Zhu, a junior specialist and first author of the study.

So far, nobody has been able to convincingly create the same types of interneurons from human pluripotent stem cells, Hunt concluded. But I think were close to being able to do this.

The study was published in Nature Communications.

See more here:
New cell therapy improves memory and stops seizures after brain injury - Drug Target Review

Innovative Biosensor Technology for Stem Cells Leads Way to Treatment of Alzheimers, Parkinsons Diseases – SciTechDaily

This unique biosensing platform consists of an array of ultrathin graphene layers and gold nanostructures. The platform, combined with high-tech imaging (Raman spectroscopy), detects genetic material (RNA) and characterizes different kinds of stem cells with greater reliability, selectivity and sensitivity than todays biosensors. Credit: Letao Yang, KiBum Lee, Jin-Ho Lee and Sy-Tsong (Dean) Chueng

A Rutgers-led team has created better biosensor technology that may help lead to safe stem cell therapies for treating Alzheimers and Parkinsons diseases and other neurological disorders.

The technology, which features a unique graphene and gold-based platform and high-tech imaging, monitors the fate of stem cells by detecting genetic material (RNA) involved in turning such cells into brain cells (neurons), according to a study in the journal Nano Letters.

Stem cells can become many different types of cells. As a result, stem cell therapy shows promise for regenerative treatment of neurological disorders such as Alzheimers, Parkinsons, stroke and spinal cord injury, with diseased cells needing replacement or repair. But characterizing stem cells and controlling their fate must be resolved before they could be used in treatments. The formation of tumors and uncontrolled transformation of stem cells remain key barriers.

A critical challenge is ensuring high sensitivity and accuracy in detecting biomarkers indicators such as modified genes or proteins within the complex stem cell microenvironment, said senior author KiBum Lee, a professor in the Department of Chemistry and Chemical Biology in the School of Arts and Sciences at Rutgers University-New Brunswick. Our technology, which took four years to develop, has demonstrated great potential for analyzing a variety of interactions in stem cells.

The teams unique biosensing platform consists of an array of ultrathin graphene layers and gold nanostructures. The platform, combined with high-tech imaging (Raman spectroscopy), detects genes and characterizes different kinds of stem cells with greater reliability, selectivity, and sensitivity than todays biosensors.

The team believes the technology can benefit a range of applications. By developing simple, rapid and accurate sensing platforms, Lees group aims to facilitate treatment of neurological disorders through stem cell therapy.

Stem cells may become a renewable source of replacement cells and tissues to treat diseases including macular degeneration, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis, according to the National Institutes of Health.

###

Reference: Dual-Enhanced Raman Scattering-Based Characterization of Stem Cell Differentiation Using Graphene-Plasmonic Hybrid Nanoarray by Letao Yang, Jin-Ho Lee, Christopher Rathnam, Yannan Hou, Jeong-Woo Choi and Ki-Bum Lee, 30 October 2019, Nano Letters.DOI: 10.1021/acs.nanolett.9b03402

The studys co-lead authors are Letao Yang and Jin-Ho Lee, postdoctoral researchers in Lees group. Rutgers co-authors include doctoral students Christopher Rathnam and Yannan Hou. A scientist at Sogang University in South Korea contributed to the study.

Read this article:
Innovative Biosensor Technology for Stem Cells Leads Way to Treatment of Alzheimers, Parkinsons Diseases - SciTechDaily

Shark Tank Season 11 Episode 8 Everything About Gallant Stem Cell Bank For Dogs As Seen on Shark Tank! Unknown Facts – TheNewsCrunch

Gallant Stem Cell Therapy For Dogs is one of the product companies to be featured on Shark Tank Season 11 Episode 8. The story behind the birth of Gallant Stem Cell Therapy For Dogs is pretty interesting. Here are some of the unknown facts about Gallant and its founders, Aaron Hirschhorn.

Aaron Hirschhorn is the founder and former-CEO of the popular dog-sitting marketplace DogVacay. Aaron is a noted entrepreneur with more than 20 years of experience in building companies and investing in them. DogVacay app was launched in 2013 and Aaron managed to raise $47 million from his erstwhile investors.

Aaron was the finalist in the Ernst & Young Entrepreneur of the Year Award 2016. In April 2017, Aarons DogVacay app merged with Rover.com and eventually went on to become a $1 billion pet services marketplace.

Trouble struck Aarons life when he suffered a massive back injury and was forced to undergo stem cell treatment which yielded amazing results to his surprise. Aaron, being an ardent dog lover wondered why this cutting-edge medical technology of stem cell transplants cannot be applied to dogs.

As a result, Gallant was born in the middle of 2018. According to Gallant, Your pups stem cells haveincredible healing power. Extract and store these powerful cells during your pets spay/neuter, so that you can unleash their potential when your best friend needs it most.

Ever since its inception, the mission of Gallant stem cell therapy is to help pets live a healthier life and make use of the epic technology of stem cell therapy in saving the lives of tons of dogs.

Dogs enter their senior years around 7 and begin feeling the effects of aging as early as 4! Traditional methods of treatment for injury and age-related conditions are expensive and can have harmful side effects. Stem cells are incredible natural healers. However, up to 99% of stem cells are lost over time due to aging. This forms the bottomline of Gallants business problem.

Gallant raised $7 million investment in August 2019.

https://gallant.com/

From the moment you entrust Gallant with your dogs stem cells, were actively invested in their long-term health and well-being. Working in tandem with you and your veterinarian, we will collect and store these powerful cells now, so down the road we can help to treat the most common health problems your dog may face. We will also update you on new and potentially life-changing treatments as they become available.

Pick your pups stem cell storage plan you dont have to have a spay/neuter procedure scheduled yet! You can always add that in later. Our proprietary process requires no additional training, so any veterinarian you trust to alter your dog is qualified. Ahead of your dogs spay/neuter, we will connect with your vet and send our collection kit directly to their office.

2. Collect

On the big day, we align with your vet before the procedure and arrange for a courier. During your dogs spay/neuter procedure, your veterinarian will take out the stem cell-rich reproductive tissue they would normally discard into the collection kit.

3. Preserve

Once the tissue is received by our scientists, we send confirmation to both you and your veterinarian. Your dogs tissue is first inspected for quality before isolating the stem cells. The stem cells are then counted and frozen in liquid nitrogen to preserve their potency in our secure, state-of-the-art laboratory. Once this process is complete, you and your veterinarian will be notified that your pets stem cells are safely stored. The cells are then monitored by our team to ensure they stay perfectly preserved.

4. Treat

Your pets stem cells are at the ready to be sent to your veterinarian if/when treatment is needed. Treatments are out-patient procedures and cost about $300. A stem cell procedure is not painful to your pet and does not require anesthesia to administer.

Gallants stem cell therapy is receiving a lot of exciting reviews online. The therapy has been successful in saving scores of dogs with conditions like osteoarthritis, skin conditions, chronic dry eye.

Gallant is offering a $395 off discount for using the code SHARKTANK

How did Gallant fare in Shark Tank Season 11? What did the Sharks have to tell about it? Did Gallant Get a Deal on Shark Tank? More information to be updated soon in this post.

Read more:
Shark Tank Season 11 Episode 8 Everything About Gallant Stem Cell Bank For Dogs As Seen on Shark Tank! Unknown Facts - TheNewsCrunch

These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News – NoCamels – Israeli Innovation News

Diabetes is a major public health crisis that is approaching epidemic proportions around the globe and growing at an alarming rate. According to the International Diabetes Federation (IDF), over 425 million adults are currently living with diabetes. That number is expected to rise to 629 million by 2045.

The disorder, which occurs when the pancreas does not produce enough insulin (the hormone that regulates blood sugar) or when the body cannot use its produced insulin, has become so deadly, that the International Diabetes Federation said it was responsible for four million deaths in 2017 alone. The World Health Organization estimated diabetes to be the seventh leading cause of death globally in 2016.

Over 350 million people are at risk of developing Type 2 diabetes, when the body becomes to resistant to insulin due to lifestyle facts such as excess weight gain, while more than 1.1 million children are living with Type 1 diabetes, the disorder that occurs when the bodys immune system attacks cells of the pancreas that produce insulin, according to the International Diabetes Federation.

World Diabetes Day, marked annually on November 14 to honor the co-discoverer of insulin Canadian Dr. Frederick Banting, born on that day in 1891, aims to raise awareness of the impact of this disease while promoting its management, care, and prevention. For the past two years (including in 2019,) the theme of World Diabetes Day has been The Family and Diabetes promoting the familys role in awareness and education of the disorder.

To mark the day, NoCamels is taking a closer look at Israels role in advancing diabetes research and treatment as well as some of the companies with cutting-edge technology that stand out in the field.

Dr. Irit Yaniv, a general manager at Accelmed Ventures II, a new $100 million venture early-stage health tech fund for medical device and digital health startups and co-founder and chairperson of Type 2 diabetes medical device startup Digma Medical, calls diabetes the most dangerous global epidemic. Israel is no exception, she says, citing half a million people living with the disease in the country.

Additionally, about 300,000 are prediabetic, a condition manifesting as borderline high blood sugar levels and an increased risk to progress to diabetes Type 2 within a few years, she explains.

Dr. Yaniv says life science entrepreneurs address the challenges presented by the epidemic in a number of ways, including creating companies and projects aimed at reducing the risk of developing the diseases, development of novel drug delivery methods for diabetes drugs, and unique medical devices for managing the disorder.

SEE ALSO: 6 Israeli Companies At The Forefront Of Diabetes Care, Prevention, and Treatment

There are a few interesting examples such as oral insulin and nasal insulin delivery systems that were developed in Israel, Yaniv says. A recent success story is Nutrino, [an Israeli] software company for the management of diabetes that was acquired by Medtronic.

Treatment for Type 2 diabetes has been focused on lifestyle changes and pharmacologic solutions. Both have challenges including patient compliance and adverse effects such as weight gain, hypoglycemia, and other reactions, Yaniv says. More than 50 percent of the patients arent able to control the disease, even with combination therapeutics.

The medical device industry has made many efforts in recent years to address this need, Yaniv says, Companies such as GI Dynamics have paved the way for new therapeutic alternatives. Digma Medical has demonstrated initial positive clinical data with its unique duodenal ablation system.

Yaniv founded Digma Medical in 2013 with Ilan Ben Oren. Backed by leading venture capital firms such as Arkin Holdings and Peregrine Ventures, the company is dedicated to the development of its DiaGone device to treat insulin resistance. DiaGone is an endoscopic, disposable device, that uses innovative laser technology to treat the duodenum, a segment of the small intestine, without an implant. The Duodenal Glycemic Control procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses DiaGone to treat the duodenum for restoring the natural ability of the body to control glucose levels, said to provide long term remission from Type 2 diabetes and other metabolic syndrome-related diseases.

For Rami Epstein, who assumed the role of CEO at stem cell company Kadimastem in May 2019, a need exists to find a better solution for the management of diabetes in order to decrease the morbidity, mortality, and costs linked to it and its medical-related care, he tells NoCamels. This method is more than just controlling insulin levels in the body. It is controlling the dose of insulin administered to the body.

All Type 1 diabetes and 30 percent of Type 2 diabetes patients depend on the daily administration of insulin in order to control their glucose levels in the blood. This is not ideal since patients have to calculate insulin dosages and take into account meal times and portions, physical activity, and other parameters, he explains. Unfortunately, many patients do not manage to stabilize their blood glucose levels properly, thereby risking complications that arise from episodes of hypoglycemia or hyperglycemia,

Through Kadimastems groundbreaking stem-cell therapy technology, developed by the companys chief scientist Professor Michel Revel at the Weizmann Institute of Science and used as the basis for the companys founding in 2009, the Ness Ziona-based firm has developed and manufactured an off-the-shelf cell product for the treatment of insulin-dependent diabetes based on its proprietary tech platform. The tech platform has been used to treat multiple diseases, including ALS, through the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical-grade functional cells.

The product, called IsletRx, is currently in pre-clinical trials. Its goal is to free patients from continuous monitoring of blood sugar levels and repeated insulin injections. The drug contains an endless source of pancreatic functional islet cells, which produce and secrete insulin and glucagon in response to external glucose levels.

Meanwhile, Tel Aviv-based clinical-stage pharmaceutical company Oramed, which is focused on the development of oral drug delivery systems, announced this week that Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, has had positive results.

The study was a 90-day, double-blind, randomized, multi-center trial designed to evaluate the safety and efficacy of ORMD-0801 as a treatment for patients with type 2 diabetes, Oramed said in a statement. The primary efficacy endpoint was a reduction in Hemoglobin A1c (A1C, also known as HbA1c, is a key clinical measure of blood glucose control) at Week 12, with no weight gain.

Israeli scientists are taking diabetes management solutions one step further and adding machine learning and AI to the mix. DreaMed Diabetes, a medical tech startup founded in 2014 to develop these types of personalized solutions, announced in September that it had received clearance from the US Food and Drug Administration (FDA) as well as a CE Mark for its DreaMed Advisor Pro, an AI-based insulin dosing decision support software. The software is for patients with Type 1 diabetes using insulin pump therapy with continuous glucose sensors and blood glucose meters (BGMs)

The decision-support platform uses proprietary algorithms to process data from a range of connected devices, including insulin pumps and self-management glucometers. The data is then analyzed to provide an optimized insulin dosing treatment plan to maintain a balanced glucose level.

SEE ALSO: Israeli AI Startup Can Predict Which Diabetes Patients Will develop Kidney Disease

This clinical and technological advance leverages the power of artificial intelligence to optimize insulin administration in a streamlined and cost-effective manner, the company said in a statement.

This year I am more optimistic that a change will happen in how we manage diabetes. We see more technology adopted in all markets, more sharing of data between patients providers and industry all for the benefit of offering better care for patients, the companys CEO Eran Atlas tells NoCamels in an email. DreaMed is happy to be part of the leaders in this effort, by offering a unique artificial intelligence technology that can analyze data and recommend in only a few seconds how to optimize the technology. With such technology, the proliferation of expert care can be achieved even in emerging markets.

Another key player operating in artificial intelligence in the diabetes management market is Sweetch. Founded in 2013, Sweetch offers an AI-based platform that aims to identify those at high risk of developing Type 2 diabetes. The company calls itself the first AI-powered therapeutics solution to help people with the disorder and comes with a mobile app and a wireless Bluetooth-connected scale. The early prevention platform announced last year that it will partner with US-based integrated healthcare system WellSpan Health and provide its app to 15,000 employees, including 200 primary care and specialty physicians, as well as advanced practice clinicians in central Pennsylvania and northern Maryland.

In 2016, the startup raised $3.5 million in a Series A round led by equity crowdfunding platform OurCrowd and Philips.

Diabetes can cause circulation problems and related conditions such as peripheral arterial disease (PAD) which occurs when plaque builds up in the arteries and reduces blood flow to the limbs. For some patients, high levels of blood glucose can damage blood vessels and cause plaque build-up affecting healthy blood flow.

The northern Israel-based startupElastiMedhas developed a wearable medical device that doesnt treat diabetes patients directly but can help the patient improve his or her circulation.

It cant treat the disease directly, but it can treat some of its symptoms, says Elastimed CEO and founder Omer Zelka.

Compression socks improve circulation by squeezing the foot and calf muscles, which straightens out the vein walls to a better working state, says Advanced Tissue, the leading wound care supply provider. Compression therapy is particularly beneficial for diabetes patients because they improve circulation in a non-invasive manner, helping to maintain the right amount of pressure in feet and legs.

ElastiMeds sock uses battery-operated technology to activate a smart material that compresses and massage the legs to stimulate circulation. The pulses mimic contractions in the calf muscles that in turn increase blood flow.

The sock provides patients with a comfortable, easy-to-wear, highly effective, and cost-effective treatment option to prevent symptoms such as swelling, blood clots, leg ulcers and reduce athletes recovery time.

ElastiMed is currently finishing an ongoing clinical study to demonstrate the safety and the feasibility of this device and its ability to increase venous blood flow. The study is led by Dr. Vered Shuster Ben-Yosef, R&D Lab Manager of the company and is currently taking place at Hillel Yaffe Medical Center in Hadera. The company currently has a working prototype and aims to get the product on the market in early 2021.

Read more here:
These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News - NoCamels - Israeli Innovation News

WCM-Q Explores Law and Ethics of Stem Cells and AI in Medicine – Al-Bawaba

The legal and ethical implications of using stem cells and artificial intelligence (AI) in medicine were discussed at the latest installment of Weill Cornell Medicine-Qatars (WCM-Q) Intersection of Law & Medicine series.

Expert speakers at the event discussed the impact of recent advances in stem cell science and AI on the practice of medicine in Qatar and explored how new legal frameworks could be developed to protect the rights and safety of patients in the MENA region. The day-long event was organized by WCM-Q in collaboration with Hamad Bin Khalifa University and the University of Malaya of Kuala Lumpur, Malaysia.

Stem cells are an exciting area for medical researchers because they have the potential to repair damaged or diseased tissues in people with conditions such as Parkinsons disease, type 1 diabetes, stroke, cancer, and Alzheimers disease, among many others. Stem cells can also be used by researchers to test new drugs for safety and effectiveness.

WCM-Qs Dr. Amal Robay, WCM-Q assistant professor in genetic medicine and director of research compliance, said: Stem cells have the capacity for unlimited or prolonged self-renewal, and they can differentiate themselves into many different cell types to become tissue- or organ-specific cells with special functions. The central ethical dilemma of stem cell science arises from the fact that embryonic stem cells are derived from human embryos or by cloning, she explained.

Visiting bioethics expert Dr. Jeremy Sugarman of Johns Hopkins University in Baltimore, US said that the public image of stem cell research had been damaged by a small number of high-profile cases in which scientists had behaved unethically. The field had also been hampered by different countries applying different laws to stem cell research, making international collaboration problematic, he said.

Meanwhile, the use of AI in healthcare has the potential to leverage analysis of large amounts of data to improve patient outcomes, but poses ethical concerns regarding privacy, the diversity of data sources, biases and relying on non-human entities for potentially life-changing decisions.

Dr. Barry Solaiman, assistant professor of law in the College of Law and Public Policy at HBKU said: Its very important that we bridge that gap between the professions of law and medicine, and that we understand the fundamental importance of ethicists to the advance of science. We need to consider how lawyers can help to develop laws to ensure that science advances and that it does so in ways that protect everyone involved.

The event, which was co-directed by Dr. Solaiman and Dr. Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q, also featured other expert speakers. Dr. Mohammad Firdaus Bin Abdul Aziz of the Faculty of Law at the University of Malaya, who spoke about stem cell regulations around the world, Dr. Faisal Farooq of Qatar Computing Research Institute, who spoke about AI in healthcare, Dr. Effy Vayena of the Swiss Institute of Technology on the ethical challenges of using machine learning in healthcare, Dr. Sharon Kaur of the Faculty of Law at the University of Malaya on global regulation of AI, and Dr. Mohammed Ghaly of Qatar Faculty of Islamic Studies on Islamic perspectives of bioethics in stem cell research. The visiting experts also engaged in two panel discussions, one examining the law and ethics of stem cell science, chaired by Dr. Adeeba Kamarulzaman, dean of medicine at the University of Malaya, and one on AI in healthcare chaired by Dr. Thurayya Arayssi, professor of clinical medicine and senior associate dean for medical education and continuing professional development at WCM-Q.

Dr. Arayssi said: I am very grateful that our expert speakers joined us to explore how legal frameworks can be developed to maximize the benefits of advances in stem cell research and AI for patients, while also respecting the rights, safety and cultural traditions of the everyone in the community.

The event was accredited locally by the Qatar Council for Healthcare Practitioners-Accreditation Department (QCHP-AD) and internationally by the Accreditation Council for Continuing Medical Education (ACCME).

Read this article:
WCM-Q Explores Law and Ethics of Stem Cells and AI in Medicine - Al-Bawaba

American Heart Association’s Research Achievement Award Presented to Harvard Scientist Peter Libby, MD, Who Discovered Role of Inflammation in CVD -…

PHILADELPHIA, Nov. 17, 2019 The American Heart Association, a global force for longer, healthier lives, has awarded its Research Achievement Award, recognizing a lifetime of extraordinary contributions to cardiovascular research, to Peter Libby, M.D., FAHA, Mallinckrodt Professor of Medicine at Harvard Medical School and a cardiovascular specialist at Brigham and Womens Hospital (BWH) in Boston.

Dr. Libbys pioneering work unraveling the role of inflammation in cardiovascular disease has been nothing short of paradigm changing. His career-long quest to understand how inflammation contributes to atherogenesis substantially deepened our understanding of heart disease, and his ability to translate his findings into the clinic has led to the development of novel new treatment strategies, said American Heart Association President Robert A. Harrington, M.D., FAHA, who presented the award.

Dr. Libbys independent research career included numerous first discoveries in the pathogenesis of atherosclerosis, including some of the mechanisms that lead to heart attack and stroke, said Dr. Harrington.

The award was presented today at the American Heart Associations Scientific Sessions 2019 in Philadelphia. The Associations Scientific Sessions is an annual, premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.

Dr. Libby instigated and helped to lead the first large-scale, randomized clinical trial establishing inflammation as a therapeutic target in cardiovascular disease. His laboratory has focused on investigating the molecular and cellular mechanisms of atherosclerosis, and he continues to lead investigations that will add to our understanding of risk factors for atherosclerotic events and heart failure, among other important research questions, the award notes.

Inflammation was not considered a critically important contributor to atherogenesis prior to Dr. Libbys investigations. Indeed, the field focused largely on lipid metabolism and proliferation of smooth muscle cells when Dr. Libby began his independent research career, noted Jonathan D. Smith, professor of molecular medicine at the Cleveland Clinic, in a letter nominating Dr. Libby for the Research Achievement Award.

Over 30 years of research, Dr. Libbys discoveries included the finding that vascular wall cells can produce, as well as respond to, pro-inflammatory cytokines (especially Interleukin-1) small proteins that are important in cell signaling.

This discovery, initially met with considerable skepticism, laid the foundation for the recognition of novel paracrine and autocrine inflammatory cytokine signaling pathways in arterial disease, a mechanism now widely validated, Smith concluded.

Dr. Libby is a longtime American Heart Association volunteer. He is also a consulting physician at the Dana-Farber Cancer Institute. He served as Chief of Cardiovascular Medicine at BWH from 1998-2014 after heading its Vascular Medicine and Atherosclerosis Unit from 1990-1997. Prior to joining BWH, Dr. Libby was at Tufts New England Medical Center in Boston.

Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Womens Hospital). He also holds an honorary Master of Arts degree from Harvard University, and honorary doctorates from the Universit de Lille, France, and Universit Laval in Qubec. He has received numerous awards and recognitions for his research accomplishments, including the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), the Special Award of the Heart Failure Association of the European Society of Cardiology (2014) and the Ernst Jung Gold Medal for Medicine( 2016.) He has received a number of other awards including several lifetime achievement awards from various organizations.

Additional Resources:

The American Heart Associations Scientific Sessions is a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians. Scientific Sessions 2019 is November 16-18 at the Pennsylvania Convention Center in Philadelphia. More than 12,000 leading physicians, scientists, cardiologists and allied health care professionals from around the world convene at the Scientific Sessions to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to over 4,100 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in the Scientific Sessions conversation on social media via #AHA19.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the publics health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

View post:
American Heart Association's Research Achievement Award Presented to Harvard Scientist Peter Libby, MD, Who Discovered Role of Inflammation in CVD -...